India's GVK BioSciences, marred by a data scandal, has signed an exclusive deal with Swedish drug developer Medivir, agreeing to handle the bulk of the biotech's chemistry work.
Chinese CRO WuXi PharmaTech is joining forces with the gene therapy experts at ReGenX Bio to hammer out a manufacturing process for the company's potential one-time treatments. Read more >>
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance. Read more >>
POPULAR COMMENT THREADS
Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.
French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost.
PRA Health Sciences, a year removed from its $300 million IPO, unveiled an end-to-end technology platform that pools trial design, planning and monitoring in one place, touting its new offering as a major step forward for the CRO.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.
Huntingdon Life Sciences, a year removed from acquiring Harlan Laboratories, is changing the combined company's name to Envigo as it works to expand its presence on the CRO market.
CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.
From Our Sister Sites
Roche heralded the late-stage success of two big trials for its multiple sclerosis drug ocrelizumab today, which they say puts them on a straight road to regulatory filings for the injectable in early 2016. But even under the best-case scenario for the future, the Big Pharma player will face a tough task squaring off against the new oral drugs that have been divvying up this big market recently.
Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.